First appearing in Wuhan, China, coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ([@bib1],[@bib2]). Given the rapid spread of this virus with consequences on an international scale, COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020 ([@bib2]). It is imperative that health care workers and researchers across all disciplines be aware of the potential impact that this disease can have on their respective fields and the medical community at large ([@bib3]).

Based on currently observed disease patterns, cardiovascular (CV) specialists will be actively engaged in the care of patients with COVID-19. The infection may directly affect cardiovascular disease (CVD). Pre-existing CVD may predispose to COVID-19 infection. Those with CVD who are infected by the virus have an elevated risk of adverse outcomes, and infection itself is associated with CV complications ([@bib4], [@bib5], [@bib6]). Moreover, COVID-19 infection may also have numerous indirect effects relevant to CV health. The large numbers of infected people requiring care may affect optimal treatment delivery to patients with acute CV conditions. Therapeutics for COVID-19 have the potential for adverse CV effects and clinicians delivering CV care are at risk of developing the illness or becoming vectors for the infection. The objective of this review is to characterize the CV impact of COVID-19, its potential consequences in patients with established CVD, as well as considerations for individual patients (with and without COVID-19), health care workers, and health systems, as understanding and addressing these issues will be crucial to optimize outcomes during the current critical period and beyond.

Methodologic Considerations {#sec1}
===========================

Given the time-sensitive nature of the challenges associated with this outbreak, we reviewed the published reports (including multiple search strategies in MEDLINE with PubMed interface) and critically assessed early reports on medRxiv, a pre-print server (date of last search: March 16, 2020). Because the initial epicenter for this outbreak was from China, the majority of data on patients with COVID-19 are from this region. Although a systematic attempt was made to include reports and viewpoints from other heavily affected countries, data related to CV risk factors or presentation were limited. This is important, because the testing strategies, care-seeking behavior, and hospitalization thresholds vary in different settings and can bias numerators and denominators, influencing estimates of the impact of the virus. This selection bias in testing, care, and reporting can lead to differences in prevalence estimates of pre-existing risk factors and patient presentation across the reports from various countries. Furthermore, the majority of the existing analyses, including those related to CV complications of COVID-19 are based on retrospective and often single-center series. Accordingly, data elements were usually reported via chart review, without external prospective ascertainment. No published or completed prospective cohort studies or randomized controlled trials were present in this publications search. These issues have important implications for research priority setting, and for interpretations of the results reported herein. There is an urgent need for high-quality research in this area, but at this point it is useful to review the available data.

Pathophysiology, Epidemiology, and Clinical Features of COVID-19 {#sec2}
================================================================

SARS-CoV-2, like other members of the Coronaviridae family, is an enveloped virus with nonsegmented, single-stranded, positive-sense ribonucleic acid (RNA) genome ([@bib1],[@bib7]). A number of SARS-related coronaviruses have been discovered in bats, and a working theory is that bats may have been the initial zoonotic host for SARS-CoV-2 given that its genome is 96.2% identical to a bat coronavirus ([@bib8]). Studies have demonstrated that SARS-CoV-2 as well as other coronaviruses can use the angiotensin-converting enzyme 2 (ACE2) protein for cell entry. ACE2 is a type I integral membrane protein that serves many important physiologic functions. It is highly expressed in lung alveolar cells, providing the main entry site for the virus into human hosts ([@bib8],[@bib9]). After ligand binding, SARS-CoV-2 enters cells via receptor-mediated endocytosis in a manner akin to human immunodeficiency virus ([@bib10]). ACE2 also serves a role in lung protection and therefore viral binding to this receptor deregulates a lung protective pathway, contributing to viral pathogenicity ([@bib11]). [Figure 1](#fig1){ref-type="fig"} depicts the potential mechanisms for ACE2 with regard to viral pathogenicity and lung protection, as well as the potential effects on this from renin-angiotensin-aldosterone inhibition as noted in the section on Drug Therapy and COVID-19.Figure 1Postulated Relationship Between SARS-CoV-2 and ACE2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin-converting enzyme 2 (ACE2) via spike protein, which facilitates entry into the cell. It is hypothesized that renin-angiotensin-aldosterone system (RAAS) inhibition may up-regulate ACE2 expression, thereby increasing viral entry and replication **(top)**. ACE2 reduces levels of angiotensin II, which is a potent proinflammatory agent in the lungs and can contribute to lung injury. RAAS inhibitors may block the production or function of angiotensin II and potentially also increase levels of ACE2, thereby indirectly inhibiting angiotensin II **(bottom)**.

Since initial identification, the disease has spread to over 100 countries across the world ([@bib1]). As of March 16, 2020, at 11:53 [am]{.smallcaps}, there have been a total of 174,961 COVID-19 cases reported globally (3,813 in the United States) associated with 6,705 deaths thus far (69 in the United States), resulting in a crude case-fatality rate of 3.8% ([@bib12],[@bib13]). Johns Hopkins University is making current data available ([@bib12],[@bib14]). The infectivity of COVID-19 is greater than that of influenza, with an estimated *R* ~0~ value (the basic reproduction number, representing viral infectivity) of 2.28 ([@bib15]). Notably, the death rate associated with COVID-19 is also considerably higher compared with the most recent World Health Organization estimate of seasonal influenza mortality rate of \<0.1%, and may reach much higher rates in elderly patients, those with comorbidities, and in those for whom efficient intensive care support is absent ([@bib13]). While other zoonotic coronaviruses, including the 2002 to 2003 SARS-CoV epidemic and the Middle East respiratory syndrome (MERS-CoV), had higher associated case fatality rates of 9.6% and 34.4%, respectively ([@bib16]), COVID-19 has resulted in many more deaths than both of these prior outbreaks combined, an issue that is in part related to the greater infectivity and higher attack rate of this virus, leading to a larger number of infected patients ([@bib16],[@bib17]). Uncertain and inconsistent disease ascertainment have resulted in variability in reported case fatality rates for several reasons, including: 1) the disease may be asymptomatic or mildly symptomatic in a large proportion of patients ([@bib16]); 2) there are inadequate testing capabilities in most geographies, leading to frequent underdiagnosis, especially in patients with less serious illness; and 3) complications and death often ensue much later than contagion (typically between 2 and 3 weeks after infection). Notably, the appraisal of SARS-CoV-2 infection may be further complicated by asymptomatic infection in a sizable portion of individuals, which may significantly contribute to further spread of infection ([@bib18]).

The clinical presentation for COVID-19 is quite variable. A large study from the Chinese Center for Disease Control and Prevention demonstrated that among 72,314 patients with COVID-19 (44,672 laboratory confirmed, 16,186 suspected, and 10,567 clinically diagnosed), the clinical severity was reported as mild in 81.4%, severe in 13.9%, and critical in 4.7% ([@bib16]). The clinical characteristics of mild COVID-19 appear to include symptoms common to other viral infections (i.e., fever, cough, dyspnea, myalgias, fatigue, and diarrhea) as well as laboratory abnormalities such as lymphopenia ([@bib19]), although knowledge of the clinical feature of the disease is evolving daily ([@bib1],[@bib20]). In severe cases, COVID-19 may present as pneumonia, the acute respiratory distress syndrome (ARDS), with or without both distributive and cardiogenic shock, to which elderly populations with pre-existing medical comorbidities are the most vulnerable ([@bib1],[@bib6],[@bib20],[@bib21]). Notably whereas rates of concomitant infections with other viruses and bacterial superinfections in preliminary data appear low ([@bib16]), patients with the most severe clinical presentations are likely still at risk for coinfections, and unsurprisingly, worse outcomes have been noted in such cases ([@bib21],[@bib22]). Children account for the minority of laboratory-confirmed cases of COVID-19 in China and appear to be less susceptible to severe disease, possibly due to stronger innate immunity, fewer comorbidities, differences in maturation of viral receptors, and/or prior exposure to other coronavirus species ([@bib23]). However, moderate-to-severe illness has been described in children as well ([@bib24]). Moreover, it is not clear how often children were being tested.

Because an extremely large and increasing number of patients have been diagnosed with COVID-19, identification of prognostic factors associated with morbidity and mortality are crucial. To date, no approved preventative vaccines or approved therapies are available for COVID-19, although several are being actively studied ([@bib25]).

Prevalence of CVD in Patients With COVID-19 {#sec3}
===========================================

The lack of widespread testing, national surveillance, and standardized data collection, as well as the potential sampling bias in sicker, hospitalized patients with more comorbidities such as CVD has complicated efforts to accurately estimate the prevalence of CVD in patients with COVID-19. Moreover, there is marked variation in testing by country. A number of studies in the available reports suggest an association between pre-existing CVD and severe COVID-19, which are summarized in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} . A meta-analysis of 6 studies inclusive of 1,527 patients with COVID-19 examined the prevalence of CVD and reported the prevalence of hypertension, cardiac and cerebrovascular disease, and diabetes to be 17.1%, 16.4%, and 9.7%, respectively ([@bib4]). Patients who required intensive care unit (ICU) admission were more likely to have these comorbidities than were non-ICU patients. Increased case-fatality rates in the previously referenced analysis of 44,672 confirmed COVID-19 cases from Wuhan, China, were noted in patients with CVD (10.5%), diabetes (7.3%), and hypertension (6.0%), all notably higher than the overall case-fatality rate of 2.3% ([@bib16]). Several smaller cohort studies have yielded similar results, suggesting higher risk for adverse events in patients with CVD who contract COVID-19, although biases related to testing and standardized data apply here as well ([@bib1],[@bib20],[@bib26], [@bib27], [@bib28], [@bib29]). Notably, whereas reports outside of China are limited, data from Italy suggest similar mortality rates and an elevated risk for death in patients with comorbidities ([@bib30]). As emerging international data become available, analysis from multinational cohorts can help inform risk stratification for severe disease especially for patients with prior CVD.Table 1Relative Frequency of CV Risk Factors or Underlying CV Conditions in Available COVID-19 Cohorts and Representative Parent PopulationsFirst Author, Year (Ref. \#)CVDDiabetesHypertensionSmokingCoronary Artery DiseaseCerebrovascular DiseaseGuan et al. 2020 ([@bib29]) (N = 1,099)---81 (7.3)165 (15.0)158 (14.4)27 (2.5)15 (1.4)Zhou et al. 2020 ([@bib6]) (N = 191)---36 (18.8)58 (30.4)11 (5.8)15 (7.9)---Wang et al. 2020 ([@bib20]) (N = 138)20 (14.5)14 (10.1)43 (31.2)------7 (5.1)Huang et al. 2020 ([@bib1]) (N = 41)6 (14.6)8 (19.5)6 (14.6)3 (7.3)------Ruan et al. 2020 ([@bib22]) (N = 150)13 (8.7)25 (16.7)52 (34.7)------12 (8.0)Wu et al. 2020 ([@bib28]) (N = 201)8 (4.0)22 (10.9)39 (19.4)---------Wu et al. 2020 ([@bib16])[∗](#tbl1fnlowast){ref-type="table-fn"} (N = 44,672)4,690 (10.5)[†](#tbl1fndagger){ref-type="table-fn"}3,261 (7.3)2,903 (6.5)---------Fang et al. 2020 ([@bib100])[∗](#tbl1fnlowast){ref-type="table-fn"} (N = 2,818)233 (8.3)[†](#tbl1fndagger){ref-type="table-fn"}206 (7.3)376 (13.3)---------Lu et al. 2018 ([@bib101])[§](#tbl1fnsection){ref-type="table-fn"} (N = 12,654)1,455 (11.5)2,125 (16.8)4,884 (38.6)4,985 (39.4)---278 (2.2)[^2][^3][^4][^5][^6]Table 2Association Among Underlying CV Risk Factors, Known CVD, and Outcomes in COVID-19Outcome VariableGuan et al. 2020 ([@bib29]) (N = 1,090)Zhou et al. 2020 ([@bib6]) (N = 191)Wang et al. 2020 ([@bib20]) (N = 138)Huang et al. 2020 ([@bib1]) (N = 41)Ruan et al. 2020 ([@bib5]) (N = 150)Wu et al. 2020 ([@bib28])[∗](#tbl2fnlowast){ref-type="table-fn"} (N = 201)**CV Risk Factors**DiabetesICU vs. non-ICU------8 (22.2) vs. 6 (5.9)1 (7.7) vs. 7 (25.0)------Severe vs. nonsevere28 (16.2) vs. 53 (5.7)---------------Dead vs. alive---17 (31.4) vs. 19 (13.9)------12 (17.6) vs. 13 (15.9)11 (25.0) vs. 5 (12.5)HypertensionICU vs. non-ICU------21 (58.3) vs. 22 (21.6)2 (15.4) vs. 4 (14.3)------Severe vs. nonsevere41 (23.7) vs. 124 (13.4)---------------Dead vs. alive---26 (48.1) vs. 32 (23.4)------29 (42.6) vs. 23 (28.0)16 (36.4) vs. 7 (17.5)SmokingICU vs. non-ICU---------0 vs. 3 (10.7)------Severe vs. non-severe38 (22.0) vs. 130 (14.0)---------------Dead vs. alive---5 (9.3) vs. 6 (4.4)------------**Known CVD**Coronary artery diseaseICU vs. non-ICU------9 (25.0) vs. 11 (10.8)---------Severe vs. nonsevere10 (5.8) vs. 17 (1.8)---------------Dead vs. alive---4 (7.4) vs. 2 (1.5)------------Cerebrovascular diseaseICU vs. non-ICU------6 (16.7) vs. 1 (1.0)---------Severe vs. nonsevere4 (2.3) vs. 11 (1.2)---------------Dead vs. alive------------7 (10.3) vs. 5 (6.1)---Cardiovascular diseaseICU vs. non-ICU---------3 (23.0) vs. 3 (10.7)------Severe vs. nonsevere------------------Dead vs. alive------------13 (19.1) vs. 04 (9.1) vs. 4 (10.0)[^7][^8][^9]

COVID-19 outcomes and CVD: Potential mechanisms of increased risk {#sec3.1}
-----------------------------------------------------------------

Mechanisms that lead to CVD are increasingly recognized to overlap with pathways that regulate immune function. For instance, age is the strongest risk factor for CVD and the effect of aging on immune function may be equally important for COVID-19 susceptibility and severity. Exemplary of this, the effect of age on the immune system is exemplified by low protective titers among 50% of adults older than 65 years who receive the influenza vaccine ([@bib31],[@bib32]). Other traditional CVD risk factors such as diabetes and hyperlipidemia affect immune function, and conversely, dysregulated immunologic status corresponds with elevated risk of incident CVD ([@bib33], [@bib34], [@bib35], [@bib36]). Thus, prevalent CVD may be a marker of accelerated immunologic aging/dysregulation and relate indirectly to COVID-19 prognosis. An increased frequency of adverse CVD events post-COVID-19 infection might also play a role in prognosis, similar to other viral infections such as influenza with mechanistic underpinnings that are complex, multifactorial, and bidirectional ([@bib37],[@bib38]). In addition, COVID-19 infection may trigger pathways unique to this pathogen that contribute to outcomes in CVD patients. For instance, higher expression of ACE2 in patients with hypertension and CVD has been postulated to enhance susceptibility to SARS-CoV-2, although the data are conflicting and without clear suggestion for treatment ([Figure 1](#fig1){ref-type="fig"}) ([@bib5]). Additional study is needed to understand the potential mechanistic relationships between CVD and COVID-19 outcomes.

Heart transplantation {#sec3.2}
---------------------

In addition to the mechanisms by which COVID-19 can affect patients with CVD risk factors, it is also important to consider COVID-19 in the context of an especially vulnerable group of patients, such as individuals awaiting or who have undergone heart transplantation. There are now case reports of COVID-19 infection among heart transplant patients ([@bib39],[@bib40]). Two heart transplant patients in China, 1 with mild and 1 with severe disease, presented with symptoms typical of COVID-19 disease. Both were managed by withholding baseline immunosuppressive regimens and treating aggressively with high-dose steroids, intravenous immunoglobulin, and antibiotics, and both survived without evidence of allograft rejection. Previous viral outbreaks have noted particularly severe infection in immunosuppressed solid organ transplant recipients ([@bib41]). Formal treatment guidelines in these patients do not exist at this time. Heart allocation teams need to consider the optimal screening strategies to prevent severe infection in recipients including whether all donor hearts should be screened, given the existence of asymptomatic COVID-19, versus limiting screening to patients with a history of symptoms or exposure of COVID-19. During the influenza A subtype H1N1 pandemic, to prevent infection in the recipient or as an impetus to initiate prophylaxis if the donor was positive, potential donors were screened if they were symptomatic or had significant exposure history ([@bib42]). Similarly, screening recipients for a history of symptoms or exposure of COVID-19 to avoid a post-transplant flare will be reasonable to be considered. Utmost precautions in infection control must be employed when interacting with these vulnerable immunosuppressed patients.

Cardiovascular Sequelae Associated With COVID-19 {#sec4}
================================================

[Figure 2](#fig2){ref-type="fig"} summarizes some of the potential CV sequelae that may result from COVID-19 infection. Pending larger studies, several existing reports are suggestive of SARS-CoV-2 infection leading to CV complications or exacerbation of pre-existing CVD ([@bib6],[@bib16],[@bib22]).Figure 2Risk Factors for Complications and Cardiovascular Sequelae of COVID-19Risk factors for complications in patients afflicted with coronavirus disease 2019 (COVID-19) and potential cardiovascular issues that may result from this disease process. CVD = cardiovascular disease.

Myocardial injury, myocarditis, and acute coronary syndromes {#sec4.1}
------------------------------------------------------------

Myocardial injury, as defined by an increased troponin level, can occur due to myocardial ischemia or nonischemic myocardial processes including myocarditis ([@bib6],[@bib43],[@bib44]). With severe respiratory infection and hypoxia, especially in the setting of severe infection and ARDS due to COVID-19, it is likely that a number of patients will develop such injury. Elevated serum troponin levels have been described in many patients infected with COVID-19, with significant differences noted between patients who died and those who survived to discharge ([@bib22],[@bib45]). In a meta-analysis of 4 studies including a total of 341 patients, standardized mean difference of cardiac troponin I levels were significantly higher in those with severe COVID-19-related illness compared with in those with nonsevere disease (25.6; 95% confidence interval \[CI\]: 6.8 to 44.5) ([@bib46]). Reports have also suggested that acute cardiac injury---which includes not only elevation of cardiac biomarkers to \>99th percentile of the upper reference limit, but also electrocardiographic and echocardiographic abnormalities---is highly prevalent in patients with COVID-19 and is associated with more severe disease and worse prognosis. Cohort studies from hospitalized patients in China estimate that such injury occurs in 7% to 17% of hospitalized patients with the disease ([@bib1],[@bib6],[@bib20]) and is significantly more common in patients admitted to the ICU (22.2% vs. 2.0%; p \< 0.001) and among those who died (59% vs. 1%; p \< 0.0001) ([@bib6],[@bib8]). However, troponin levels can be exacerbated in patients with renal insufficiency due to delayed excretion, which is common in patients with advanced disease. Given limited high-quality data, and the heterogeneity of definitions across the studies, standardized data collection methods are recommended using the most recent Universal Definition of Myocardial Infarction (MI) ([@bib44]).

Prior studies in other coronavirus species (MERS-CoV) have demonstrated evidence of acute myocarditis using cardiac magnetic resonance imaging ([@bib47]), and myocardial inflammation and damage have been reported with COVID-19 infection. Among 68 deaths in a case series of 150 patients with COVID-19, 7% were attributed to myocarditis with circulatory failure and 33% to cases in which myocarditis may have played a contributing role to the patient's demise ([@bib22]). Other reports have described fulminant myocarditis in the setting of high viral load with autopsy findings of inflammatory mononuclear infiltrate in myocardial tissue ([@bib27],[@bib48],[@bib49]). While glucocorticoid therapy and other agents have been administered ([@bib50]), the most effective treatment strategy for such patients is yet to be defined. Pericardial involvement has not yet been reported, but further study is needed. Pericardial involvement has not yet been reported but further study is needed. In addition, the extent to which supply and demand mismatch (type 2 MI) in patients with underlying CVD have contributed to the CV manifestations of the syndrome is uncertain.

Case reports of acute coronary syndromes (type 1 MI) in the setting of COVID-19 have yet to be published. Nonetheless, the profound inflammatory response and hemodynamic changes associated with severe disease may confer risk for atherosclerotic plaque rupture in susceptible patients ([@bib6]). In this regard, analysis by Kwong et al. ([@bib37]) demonstrated that patients with acute respiratory infections are at elevated risk for subsequently developing acute MI after influenza (incidence ratio: 6.1; 95% CI: 3.9 to 9.5) and after noninfluenza viral illnesses including other coronavirus species (incidence ratio: 2.8; 95% CI: 1.2 to 6.2). The development of care pathways and protocols for COVID-19 patients with ST-segment elevation MI suggest that both within and outside of China such a clinical scenario is highly probable ([@bib51]).

Additionally, it is important to note potential overlapping symptomatology between acute coronary syndromes and COVID-19. Even though the predominant presenting symptoms of COVID-19 are respiratory, a case report described a patient in Italy with chest pain and electrocardiographic changes for which the cardiac catheterization lab was activated. Notably, the patient was found to be free of obstructive coronary artery disease but ultimately tested positive for COVID-19 ([@bib52]). Moving forward as the virus continues to infect patients with significant CV risk factors or established CVD, cases of acute coronary syndromes in the setting of COVID-19 are likely to develop. The true prevalence in this setting may be under-reported given the logistical challenges associated with limited testing and cardiac catheterization laboratory availability in the setting of this outbreak. For further recommendations for the care and management of COVID-19 patients in the cardiac catheterization laboratory, please see the joint American College of Cardiology and Society of Cardiovascular Angiography and Intervention guidance statement ([@bib53]).

Cardiac arrhythmia and cardiac arrest {#sec4.1.1}
-------------------------------------

Cardiac arrhythmias are another common CV manifestation described in patients with COVID-19 infection. Though nonspecific, heart palpitations were part of the presenting symptomology in 7.3% of patients in a cohort of 137 patients admitted for COVID-19 disease ([@bib27]). In hospitalized COVID-19 patients, cardiac arrhythmia was noted in 16.7% of 138 patients in a Chinese cohort and was more common in ICU patients than in non-ICU patients (44.4% vs. 6.9%) ([@bib20]). Unfortunately, specifics about the types of arrhythmias that occur in these patients are yet to be published or presented. High prevalence of arrhythmia might be, in part, attributable to metabolic disarray, hypoxia, or neurohormonal or inflammatory stress in the setting of viral infection in patients with or without prior CVD. However, new onset of malignant tachyarrhythmias in the setting of troponin elevation should raise suspicion for underlying myocarditis ([@bib45],[@bib54]).

Cardiomyopathy and heart failure {#sec4.1.2}
--------------------------------

Zhou et al. ([@bib6]) reported that heart failure was observed in 23.0% of patients with COVID-19 presentations. Notably, heart failure was more commonly observed than acute kidney injury in this cohort and was more common in patients who did not survive the hospitalization than in those who did survive (51.9% vs. 11.7%). Whether heart failure is most commonly due to exacerbation of pre-existing left ventricular dysfunction versus new cardiomyopathy (either due to myocarditis or stress cardiomyopathy) remains unclear ([@bib55]). Right heart failure and associated pulmonary hypertension should be also considered, in particular in the context of severe parenchymal lung disease and ARDS.

Cardiogenic and mixed shock {#sec4.1.3}
---------------------------

The predominant clinical presentation of COVID-19 is acute respiratory illness, which may lead to ARDS manifested as ground-glass opacities on chest imaging ([@bib56]) and hypoxemia. However, similar features may be seen in the case of de novo or coexisting cardiogenic pulmonary edema. As such, it is important to consider cardiogenic or mixed cardiac plus primary pulmonary causes of respiratory manifestations in COVID-19. Historically, right heart catheterization was used to determine pulmonary capillary wedge pressure to aid in this distinction, although this has been removed from the Berlin criteria used for the diagnosis of ARDS. Rather, the Berlin criteria use timing of symptom onset, imaging with bilateral pulmonary opacities, and lack of volume overload to identify patients with ARDS ([@bib57]). In many cases, serum brain natriuretic peptide and echocardiography can help clarify the diagnosis ([@bib58],[@bib59]). However, if these tests are unclear and there remains concern for mixed presentation, pulmonary artery catheterization should be considered in select cases to assess filling pressures, cardiac output, and to guide clinical decision making, given the different management approaches for ARDS and cardiogenic shock. Finally, it is crucial to determine whether a concomitant cardiogenic component is present when considering mechanical respiratory and circulatory support with extracorporeal membranous oxygenation (ECMO) or other techniques, as this may lead to changes in device selection (e.g., venovenous vs. venoarterial ECMO cannulation). Regardless, in the most severe of infections with ARDS and necrotizing pneumonias, patient prognosis may be poor even with ECMO support. In a case series of 52 critically ill patients with COVID-19, 83.3% (5 of 6) of patients who were treated with ECMO did not survive. Further studies regarding the utility of ECMO support in advanced COVID-19, including which patients may (or may not) benefit and whether concomitant left ventricular venting should be done, are warranted ([@bib60]).

Venous thromboembolic disease {#sec4.1.4}
-----------------------------

COVID-19 infected patients are likely at increased risk of venous thromboembolism, and data from Klok et al. ([@bib61]) suggests that rates of thrombotic complications may be as high as 31% in critically ill patients with COVID-19. Reports suggest abnormal coagulation parameters in hospitalized patients with severe COVID-19 disease ([@bib62],[@bib63]). In a multicenter retrospective cohort study from China, elevated D-dimer levels (\>1 g/l) were strongly associated with in-hospital death, even after multivariable adjustment (odds ratio: 18.4; 95% CI: 2.6 to 128.6; p = 0.003) ([@bib6]). In another study comparing COVID-19 survivors to nonsurvivors, nonsurvivors had significantly higher D-dimer and fibrin degradation products levels, and 71.4% of nonsurvivors met clinical criteria for disseminated intravascular coagulation during the course of their disease ([@bib62]). In addition to disseminated intravascular coagulation, critically ill patients with prolonged immobilization are inherently at high risk for venous thromboembolism. Vascular inflammation may also contribute to the hypercoagulable state and endothelial dysfunction in such patients. In the setting of critically ill COVID-19 patients who demonstrate clinical deterioration as evidenced by hypoxia or hemodynamic instability, thromboembolic disease should be considered. Retrospective data from 97 patients with severe COVID-19, the majority of whom received prophylactic dose low--molecular-weight heparin in the setting of sepsis-induced coagulopathy, suggests that anticoagulation in such patients may be associated with lower mortality rates ([@bib64]). The optimal thromboprophylactic regimen for patients hospitalized with COVID-19-related illness is not known, however. As such, contemporary guideline-endorsed strategies should be observed ([@bib65]). Given the drug-drug interactions between some antiviral treatments and direct oral anticoagulants, low molecular weight heparins or unfractionated heparin with or without mechanical prophylaxis are likely to be preferred in acutely ill hospitalized patients.

Drug Therapy and COVID-19: Interactions and Cardiovascular Implications {#sec5}
=======================================================================

Data regarding antiviral therapies and other treatment strategies, as well as their potential interaction with CV medications and CV toxicities are summarized in [Tables 3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"}, and [5](#tbl5){ref-type="table"} . Although currently there are no specific effective therapies for COVID-19, various pharmacologic agents are under active investigation. As these drugs are being studied, it is important to review the potential CV side effects and interactions with other CV medications.Table 3Antiviral Therapies Currently Being Studied for COVID-19: Potential Cardiovascular Interactions and ToxicitiesAntiviral TherapyClinicalTrials.gov IdentifiersMechanism of ActionCV Drug Class InteractionsCV Adverse EffectsRemdesevir[NCT04302766](https://clinicaltrials.gov/ct2/show/NCT04302766?term=NCT04302766&draw=2&rank=1){#intref0080}\
[NCT04280705](https://clinicaltrials.gov/ct2/show/NCT04280705?term=NCT04280705&draw=2&rank=1){#intref0085}\
[NCT04292899](https://clinicaltrials.gov/ct2/show/NCT04292899?term=NCT04292899&draw=2&rank=1){#intref0090}\
[NCT04292730](https://clinicaltrials.gov/ct2/show/NCT04292730?term=NCT04292730&draw=2&rank=1){#intref0095}\
[NCT04315948](https://clinicaltrials.gov/ct2/show/NCT04315948?term=NCT04315948&draw=2&rank=1){#intref0100}\
[NCT04321616](https://clinicaltrials.gov/ct2/show/NCT04321616?term=NCT04321616&draw=1&rank=1){#intref0105}Nucleotide-analog inhibitor of RNA-dependent RNA polymerasesN/AUnknownRibavirin[NCT04276688](https://clinicaltrials.gov/ct2/show/NCT04276688?term=NCT04276688&draw=2&rank=1){#intref0110}\
[NCT00578825](https://clinicaltrials.gov/ct2/show/NCT00578825?term=NCT00578825&draw=2&rank=1){#intref0115}Inhibits replication of RNA and DNA virusesAnticoagulants[∗](#tbl3fnlowast){ref-type="table-fn"}Drug-induced hemolytic anemia Avoid in patients with significant/unstable cardiac diseaseLopinavir/ritonavir[NCT04252885](https://clinicaltrials.gov/ct2/show/NCT04252885?term=NCT04252885&draw=2&rank=1){#intref0120}\
[NCT04275388](https://clinicaltrials.gov/ct2/show/NCT04275388?term=NCT04275388&draw=2&rank=1){#intref0125}\
[NCT04276688](https://clinicaltrials.gov/ct2/show/NCT04276688?term=NCT04276688&draw=2&rank=1){#intref0130}\
[NCT04286503](https://clinicaltrials.gov/ct2/show/NCT04286503?term=NCT04286503&draw=2&rank=1){#intref0135}\
[NCT04307693](https://clinicaltrials.gov/ct2/show/NCT04307693?term=NCT04307693&draw=2&rank=1){#intref0140}\
[NCT04261907](https://clinicaltrials.gov/ct2/show/NCT04261907?term=NCT04261907&draw=2&rank=1){#intref0145}\
[NCT02845843](https://clinicaltrials.gov/ct2/show/NCT02845843?term=NCT02845843&draw=2&rank=1){#intref0150}\
[NCT04321174](https://clinicaltrials.gov/ct2/show/NCT04321174?term=NCT04321174&draw=2&rank=1){#intref0155}\
[NCT04295551](https://clinicaltrials.gov/ct2/show/NCT04295551?term=NCT04295551&draw=2&rank=1){#intref0160}\
[NCT04315948](https://clinicaltrials.gov/ct2/show/NCT04315948?term=NCT04315948&draw=1&rank=1){#intref0165}\
[NCT04251871](https://clinicaltrials.gov/ct2/show/NCT04251871?term=NCT04251871&draw=2&rank=1){#intref0170}\
[NCT00578825](https://clinicaltrials.gov/ct2/show/NCT00578825?term=NCT00578825&draw=2&rank=1){#intref0175}\
[NCT04328012](https://clinicaltrials.gov/ct2/show/NCT04328012?term=lopinavir%2Fritonavir+covid-19&draw=2&rank=8){#intref0180}\
[NCT04321993](https://clinicaltrials.gov/ct2/show/NCT04321993?term=NCT04321993&draw=1&rank=1){#intref0185}Lopinavir is a protease inhibitor; ritonavir inhibits CYP3A metabolism increasing levels of lopinavirAntiplatelets[∗](#tbl3fnlowast){ref-type="table-fn"}\
Anticoagulants[∗](#tbl3fnlowast){ref-type="table-fn"}\
Statin[∗](#tbl3fnlowast){ref-type="table-fn"}\
Antiarrhythmics[∗](#tbl3fnlowast){ref-type="table-fn"}Altered cardiac conduction: QTc prolongation, high-degree AV block, torsade de pointes; increased serum cholesterol[^10][^11][^12]Table 4Other Therapies Being Studied for COVID-19: Potential Cardiovascular Interactions and ToxicitiesTherapyClinicalTrials.gov\
IdentifiersMechanism of ActionCV Drug\
InteractionsCV Adverse\
EffectsAnakinra[NCT04341584](https://clinicaltrials.gov/ct2/show/NCT04341584?term=NCT04341584&draw=2&rank=1){#intref0190}\
[NCT04339712](https://clinicaltrials.gov/ct2/show/NCT04339712?term=NCT04339712&draw=2&rank=1){#intref0195}\
[NCT04330638](https://clinicaltrials.gov/ct2/show/NCT04330638?term=NCT04330638&draw=1&rank=1){#intref0200}Recombinant human decoy IL-1Ra. Blocks IL-1α and IL-1β. IL-1β overproduction is associated with the pathogenesis of macrophage activation syndrome.NoneNoneBevacizumab[NCT04275414](https://clinicaltrials.gov/ct2/show/NCT04275414?term=NCT04275414&draw=2&rank=1){#intref0205}COVID-19 patients may have elevated VEGF levels. Inhibits VEGF and decreases vascular permeability and pulmonary edema.NoneDirect myocardial toxicity vs. exacerbation of underlying cardiomyopathy\
Severe hypertension\
Thromboembolic eventsChloroquine/hydroxychloroquine[NCT04303507](https://clinicaltrials.gov/ct2/show/NCT04303507?term=NCT04303507&draw=2&rank=1){#intref0210}\
[NCT04307693](https://clinicaltrials.gov/ct2/show/NCT04307693?term=NCT04307693&draw=2&rank=1){#intref0215}\
[NCT04318444](https://clinicaltrials.gov/ct2/show/NCT04318444?term=NCT04318444&draw=1&rank=1){#intref0220}\
[NCT04341493](https://clinicaltrials.gov/ct2/show/NCT04341493?term=NCT04341493&draw=1&rank=1){#intref0225}\
[NCT04316377](https://clinicaltrials.gov/ct2/show/NCT04316377?term=NCT04316377&draw=2&rank=1){#intref0230}\
[NCT04333654](https://clinicaltrials.gov/ct2/show/NCT04333654?term=NCT04333654&draw=1&rank=1){#intref0235}\
[NCT04322123](https://clinicaltrials.gov/ct2/show/NCT04322123?term=NCT04322123&draw=1&rank=1){#intref0240}\
[NCT04307693](https://clinicaltrials.gov/ct2/show/NCT04307693?term=NCT04307693&draw=2&rank=1){#intref0245}\
[NCT04261517](https://clinicaltrials.gov/ct2/show/NCT04261517?term=NCT04261517&draw=2&rank=1){#intref0250}\
[NCT04341727](https://clinicaltrials.gov/ct2/show/NCT04341727?term=NCT04341727&draw=1&rank=1){#intref0255}\
[NCT04328961](https://clinicaltrials.gov/ct2/show/NCT04328961?term=NCT04328961&draw=1&rank=1){#intref0260}\
[NCT04321278](https://clinicaltrials.gov/ct2/show/NCT04321278?term=NCT04321278&draw=2&rank=1){#intref0265}\
[NCT04342169](https://clinicaltrials.gov/ct2/show/NCT04342169?term=NCT04342169&draw=1&rank=1){#intref0270}\
[NCT04332835](https://clinicaltrials.gov/ct2/show/NCT04332835?term=NCT04332835&draw=1&rank=1){#intref0275}\
[NCT04332991](https://clinicaltrials.gov/ct2/show/NCT04332991?term=NCT04332991&draw=1&rank=1){#intref0280}\
[NCT04315948](https://clinicaltrials.gov/ct2/show/NCT04315948?term=NCT04315948&draw=1&rank=1){#intref0285}\
[NCT04334967](https://clinicaltrials.gov/ct2/show/NCT04334967?term=NCT04334967&draw=2&rank=1){#intref0290}\
[NCT04321993](https://clinicaltrials.gov/ct2/show/NCT04321993?term=NCT04321993&draw=1&rank=1){#intref0295}\
[NCT04342221](https://clinicaltrials.gov/ct2/show/NCT04342221?term=NCT04342221&draw=1&rank=1){#intref0300}\
[NCT04321616](https://clinicaltrials.gov/ct2/show/NCT04321616?term=NCT04321616&draw=1&rank=1){#intref0305}\
[NCT04338698](https://clinicaltrials.gov/ct2/show/NCT04338698?term=NCT04338698&draw=2&rank=1){#intref0310}\
[NCT04315896](https://clinicaltrials.gov/ct2/show/NCT04315896?term=NCT04315896&draw=1&rank=1){#intref0315}\
[NCT04328012](https://clinicaltrials.gov/ct2/show/NCT04328012?term=NCT04328012&draw=1&rank=1){#intref0320}\
[NCT04330586](https://clinicaltrials.gov/ct2/show/NCT04330586?term=NCT04330586&draw=1&rank=1){#intref0325}Alters endosomal pH required for virus/cell fusion and interferes with glycosylation of SARS-CoV-2 cellular receptors.Antiarrhythmics[∗](#tbl4fnlowast){ref-type="table-fn"}Direct myocardial toxicity vs. exacerbation of underlying cardiomyopathy\
Altered cardiac conduction: AV block, bundle-branch block, QT prolongation, torsades de pointes, ventricular tachycardia/fibrillationColchicine[NCT04322682](https://clinicaltrials.gov/ct2/show/NCT04322682?term=NCT04322682&draw=1&rank=1){#intref0330}\
[NCT04326790](https://clinicaltrials.gov/ct2/show/NCT04326790?term=NCT04326790&draw=1&rank=1){#intref0335}\
[NCT04322565](https://clinicaltrials.gov/ct2/show/NCT04322565?term=NCT04322565&draw=1&rank=1){#intref0340}Anti-inflammatory properties to potentially inhibit the pathogenetic cycle of SARS-COV-2 by counteracting the assembly of the NLRP3 inflammasome and (less likely) to inhibit viral endocytosis in myocardial and respiratory cells.Non-DHP CCB[∗](#tbl4fnlowast){ref-type="table-fn"}\
Statins[∗](#tbl4fnlowast){ref-type="table-fn"}\
Antiarrhythmics[∗](#tbl4fnlowast){ref-type="table-fn"}NoneEculizumab[NCT04288713](https://clinicaltrials.gov/ct2/show/NCT04288713?term=NCT04288713&draw=2&rank=1){#intref0345}Inhibits complement activation and prevents the formation of the membrane attack complex.NoneHypertension or hypotension, tachycardia, peripheral edemaFingolimod[NCT04280588](https://clinicaltrials.gov/ct2/show/NCT04280588?term=NCT04280588&draw=2&rank=1){#intref0350}Inhibits lymphocytes through sphingosine-1 phosphate regulation.Antiarrhythmics[∗](#tbl4fnlowast){ref-type="table-fn"}Hypertension, first and second degree AV block (contraindicated with high degree AV block and sick sinus syndrome), bradycardia, QTc prolongation (contraindicated if QTc ≥500 ms)\
Contraindicated after myocardial infarction, unstable angina, CVA/TIA, ADHF in previous 6 monthsInterferon-alpha, beta[NCT04275388](https://clinicaltrials.gov/ct2/show/NCT04275388?term=NCT04275388&draw=2&rank=1){#intref0355}\
[NCT04273763](https://clinicaltrials.gov/ct2/show/NCT04273763?term=NCT04273763&draw=2&rank=1){#intref0360}\
[NCT04276688](https://clinicaltrials.gov/ct2/show/NCT04276688?term=NCT04276688&draw=2&rank=1){#intref0365}\
[NCT04293887](https://clinicaltrials.gov/ct2/show/NCT04293887?term=NCT04293887&draw=2&rank=1){#intref0370}\
[NCT04251871](https://clinicaltrials.gov/ct2/show/NCT04251871?term=NCT04251871&draw=2&rank=1){#intref0375}\
[NCT04320238](https://clinicaltrials.gov/ct2/show/NCT04320238?term=NCT04320238&draw=1&rank=1){#intref0380}\
[NCT02845843](https://clinicaltrials.gov/ct2/show/NCT02845843?term=NCT02845843&draw=2&rank=1){#intref0385}\
[NCT04291729](https://clinicaltrials.gov/ct2/show/NCT04291729?term=NCT04291729&draw=2&rank=1){#intref0390}\
[NCT04315948](https://clinicaltrials.gov/ct2/show/NCT04315948?term=NCT04315948&draw=1&rank=1){#intref0395}Immune activation.WarfarinDirect myocardial toxicity vs. exacerbation of underlying cardiomyopathy\
Reports of: hypotension, arrhythmia, cardiomyopathy, myocardial infarctionPirfenidone[NCT04282902](https://clinicaltrials.gov/ct2/show/NCT04282902?term=NCT04282902&draw=2&rank=1){#intref0400}Antifibrotic ability, possible IL-1β and IL-4 inhibition to reduce cytokine storm and resultant pulmonary fibrosis.NoneNoneMethylprednisolone[NCT04273321](https://clinicaltrials.gov/ct2/show/NCT04273321?term=NCT04273321&draw=2&rank=1){#intref0405}\
[NCT04244591](https://www.clinicaltrials.gov/ct2/show/NCT04244591){#intref0410}\
[NCT04323592](https://clinicaltrials.gov/ct2/show/NCT04323592?term=NCT04323592&draw=1&rank=1){#intref0415}Alters gene expression to reduce inflammation.WarfarinFluid retention\
Electrolyte disturbances\
HypertensionSarilumab[NCT04324073](https://clinicaltrials.gov/ct2/show/NCT04324073?term=NCT04324073&draw=2&rank=1){#intref0420}\
[NCT04327388](https://clinicaltrials.gov/ct2/results?cond=&term=NCT04327388&cntry=&state=&city=&dist=){#intref0425}\
[NCT04322773](https://clinicaltrials.gov/ct2/show/NCT04322773?term=NCT04322773&draw=1&rank=1){#intref0430}Binds to both soluble and membrane-bound IL-6Rs and inhibit signaling that could help mitigate cytokine storm.Antiplatelets[∗](#tbl4fnlowast){ref-type="table-fn"}\
Anticoagulants[∗](#tbl4fnlowast){ref-type="table-fn"}\
Statins[∗](#tbl4fnlowast){ref-type="table-fn"}\
Antiarrhythmics[∗](#tbl4fnlowast){ref-type="table-fn"}UnknownTocilizumab[NCT04306705](https://clinicaltrials.gov/ct2/show/NCT04306705?term=NCT04306705&draw=2&rank=1){#intref0435}\
[NCT04335071](https://clinicaltrials.gov/ct2/show/NCT04335071?term=NCT04335071&draw=1&rank=1){#intref0440}\
[NCT04331808](https://clinicaltrials.gov/ct2/show/NCT04331808?term=NCT04331808&draw=1&rank=1){#intref0445}\
[NCT04310228](https://clinicaltrials.gov/ct2/show/NCT04310228?term=NCT04310228&draw=1&rank=1){#intref0450}\
[NCT04339712](https://clinicaltrials.gov/ct2/show/NCT04339712?term=NCT04339712&draw=1&rank=1){#intref0455}\
[NCT04330638](https://clinicaltrials.gov/ct2/show/NCT04330638?term=NCT04330638&draw=1&rank=1){#intref0460}Inhibits IL-6 receptor.Antiplatelets[∗](#tbl4fnlowast){ref-type="table-fn"}\
Anticoagulants[∗](#tbl4fnlowast){ref-type="table-fn"}\
Statins[∗](#tbl4fnlowast){ref-type="table-fn"}\
Evolocumab\
Beta blockers[∗](#tbl4fnlowast){ref-type="table-fn"}\
Antiarrhythmics[∗](#tbl4fnlowast){ref-type="table-fn"}Hypertension\
Increased serum cholesterolTranexamic acid[NCT04338126](https://clinicaltrials.gov/ct2/show/NCT04338126?term=NCT04338126&draw=1&rank=1){#intref0465}\
[NCT04338074](https://clinicaltrials.gov/ct2/show/NCT04338074?term=NCT04338074&draw=1&rank=1){#intref0470}Reduced conversion of plasminogen to plasmin could potentially reduce the infectivity and virulence of the virus.NoneVenous and arterial thrombosis and thromboembolism, including retinal artery/vein obstruction, has been reported\
Use caution in patients with uncorrected cardiovascular or cerebrovascular disease due to complications of thrombosis[^13][^14][^15]Table 5Recommendations Regarding Dosing and Adjustment in the Setting of Medication InteractionsTherapySpecific InteractionMOA of Drug Interaction and Specific Dose AdjustmentsOther NotesChloroquine / hydroxychloroquineBeta-blockersMetoprolol, carvedilol, propranolol, labetalolCYP2D6 inhibition:Dose reduction for beta-blockers may be requiredAntiarrhythmicsQT-prolongingIntensified QTc prolongationMonitor ECGDigoxinP-glycoprotein inhibition:Dose reduction for digoxin may be neededMonitor digoxin levelsColchicineNon-DHP CCBVerapamilDiltiazemCCB-Induced CYP3A4 and P-glycoprotein inhibition:See package insert for dose reduction recommendations based on dosing scheme.Monitor for signs of colchicine toxicity.StatinsSimvastatinAtorvastatinFluvastatinLovastatinPravastatinPotential CYP3A4 inhibition or impaired excretion:No specific dose reductions in statins recommendedMonitor for signs of muscle pain and/or weakness with concomitant therapyAntiarrhythmicsDigoxinP-glycoprotein inhibition:Dose reduction for digoxin may be neededMonitor digoxin levelsFingolimodBradycardia-causing medicationsBeta blockers, calcium-channel blockers, ivabradineInhibition of sphingosine-1-phosphate on atrial myocytes can decrease AV conduction; if co-administration is necessary, overnight continuous ECG monitoring recommended after first doseStop AV nodal blocking medications if possible.QT-prolonging antiarrhythmicsClass Ia antiarrhythmicsClass III antiarrhythmicsDo not co-administerMonitor ECGInterferon-alpha, betaWarfarinUnknown mechanism of action:Decreased dose may be neededMonitor INRLopinavir/ritonavirAnticoagulantsApixabanEdoxabanRivaroxabanWarfarinCYP3A4 and P-glycoprotein inhibition:Apixaban: administered at 50% of dose (do not administer if requirement 2.5 mg twice daily)Rivaroxaban: do not co-administerP-glycoprotein inhibition:Edoxaban: do not co-administerCYP2C9 induction (99):May decrease serum concentration of warfarinDabigatran and warfarin can be administered with caution\
Monitor INR with warfarinAntiplateletsClopidogrelTicagrelorCYP3A4 inhibition:Reduction in clopidogrel active metabolite. Do not co-administerIncreased effect of ticagrelor; do not co-administerBased on limited evidence, recommend prasugrel if no contraindicationsStatinsAtorvastatinRosuvastatinLovastatinSimvastatinOATTP1B1 and BCRP inhibition:Rosuvastatin: dose adjust to maximum dose of 10 mg/dayCYP3A4 inhibition or transporter- related inhibition:Atorvastatin: adjust to maximum dose of 20 mg/dayLovastatin and simvastatin: do not co-administerStart at lowest possible dose of rosuvastatin and atorvastatin and titrate up\
Can consider pitavastatin and pravastatinAntiarrhythmicsQT-prolonging medicationDigoxinRanolazineIntensified QTc prolongation P-glycoprotein inhibition:Consider reducing digoxin dosing by 30%-50%CYP3A4 inhibitionRanolazine: do not co-administerMonitor ECG\
Monitor digoxin levelIvabradineCYP3A4 inhibition:Do not co-administerMethylprednisoloneAnticoagulantsWarfarinUnknown mechanism:Decreased dose may be neededMonitor INRRemdesivirN/APotential inducer of CYP1A2, CYP2B6 and CYP3A4\
No dose adjustment recommendedN/ARibavirinAnticoagulantsWarfarinUnknown mechanism of action:Increased dose may be neededMonitor INRSarilumabAnticoagulantsApixabanRivaroxabanWarfarinAntiplateletsTicagrelorClopidogrelStatinsSimvastatinAtorvastatinLovastatinAntiarrhythmicsAmiodaroneIncreased CYP3A4 expression:No dose adjustment recommendedMonitor INR\
Monitor ECGTocilizumabAnticoagulantsApixabanRivaroxabanWarfarinAntiplateletsTicagrelorClopidogrelStatinsSimvastatinAtorvastatinLovastatinBeta-blockersMetoprolol, carvedilol, propranolol, labetalolAntiarrhythmicsAmiodaroneCan increase expression of CYP1A2, 2B6, 2C9, 2C19, 2D6, 3A4 leading to increased metabolism. No dose adjustment recommendationMonitor INR\
Monitor ECG[^16]

Antiviral therapy {#sec5.1}
-----------------

Antivirals are at the forefront of medications under study for the treatment COVID-19 and the clinical trial identifiers for each are listed in [Table 3](#tbl3){ref-type="table"}. Ribavirin and remdesivir are 2 such agents that bind to the active site on the RNA-dependent RNA polymerase on SARS-CoV-2 ([@bib66]), whereas lopinavir/ritonavir inhibits replication of RNA virus and has evidence of a synergistic effect in vitro with ribavirin ([@bib67]). Ribavirin and lopinavir/ritonavir are under investigation in clinical trials for COVID-19 and have been used for years as components of treatment for hepatitis C and human immunodeficiency virus, respectively ([@bib68],[@bib69]). Whereas ribavirin has no characterized direct CV toxicity, lopinavir/ritonavir may result in QT- and PR-interval prolongation, especially in patients who have a baseline abnormality (long QT) or those who are at risk for conduction abnormalities including those taking other QT prolonging drugs ([@bib69]). Both ribavirin and lopinavir/ritonavir have the potential to affect anticoagulant dosing: ribavirin has variable effects on warfarin dosing ([@bib70]) and lopinavir/ritonavir may require dose reductions or avoidance of CYP3A-mediated drugs such as rivaroxaban and apixaban ([@bib71],[@bib72]).

Lopinavir/ritonavir can also influence the activity of P2Y~12~ inhibitors through CYP3A4 inhibition, which results in decreased serum concentrations of the active metabolites of clopidogrel and prasugrel and increased serum concentrations of ticagrelor. The active metabolite for clopidogrel is mostly formed by CYP2C19, but several other CYP enzymes contribute, including CYP1A2, 2B6, and 3A ([@bib73],[@bib74]). Given the increase in serum ticagrelor levels with such medications ([@bib75],[@bib76]), concomitant use with ticagrelor is discouraged in the United States and Canada due to excess in bleeding risk. Conversely, there is evidence that clopidogrel may not always provide sufficient platelet inhibition in the setting of concomitant administration of ritonavir, whereas this was not the case with prasugrel as assessed by the VerifyNow P2Y~12~ assay (Accumetrics, San Diego, California) ([@bib73],[@bib74]). If P2Y~12~ inhibition is needed during treatment with lopinavir/ritonavir, prasugrel can be used; however, if contraindicated (i.e., history of stroke or transient ischemic attack, low body mass index, or active pathological bleeding), a testing-guided approach (e.g., with P2Y~12~ platelet function assays) may be considered with alternate antiplatelet agents. Details about switching between P2Y~12~ inhibitors have been described elsewhere ([@bib77]). Finally, metabolism of the intravenous P2Y~12~ inhibitor, cangrelor, is independent of hepatic function, therefore a drug interaction is not expected ([@bib78]).

β-Hydroxy-β-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) also have the potential to interact with the combination of lopinavir/ritonavir and can result in myopathy due to elevated statin levels when administered together. Lovastatin and simvastatin, in particular, are contraindicated for coadministration with lopinavir/ritonavir due to risk of rhabdomyolysis. Other statins, including atorvastatin and rosuvastatin, should be administered at the lowest possible dose but not to exceed the maximum dose stated in the package insert while on lopinavir/ritonavir ([@bib69]).

Remdesivir is an investigational drug previously evaluated in the Ebola epidemic and is now being studied in patients with COVID-19. The drug is currently available in clinical trials and through compassionate use from Gilead Sciences, Inc. (Foster City, California). Whereas extensive CV toxicities and medication interactions have yet to be reported, prior evaluation of this drug during the Ebola outbreak did note the development of hypotension and subsequent cardiac arrest after loading dose in 1 patient (among 175 total) ([@bib79]).

Other treatments {#sec5.2}
----------------

[Table 4](#tbl4){ref-type="table"} presents information on other treatments being studied for COVID-19 (including ClinicalTrials.gov identifiers). In addition to antiviral medications, numerous immune-modulating and secondary medications to prevent complications that could arise from COVID-19 are currently being investigated. Chloroquine, which has been used as an antimalarial agent, blocks virus infection by increasing the endosomal pH required for virus/cell fusion and has been demonstrated in vitro to have inhibitory activity in SARS-CoV-2 ([@bib80],[@bib81]). Chloroquine and the closely related hydroxychloroquine have the potential for intermediate-to-delayed myocardial toxicity. Risk factors include long-term exposure (\>3 months), higher weight-based dose, pre-existing cardiac disease, and renal insufficiency ([@bib82]). Chloroquine cardiac toxicity presents as restrictive or dilated cardiomyopathy or conduction abnormalities thought to be due to intracellular inhibition of lysosomal enzymes in the myocyte ([@bib82],[@bib83]). In addition, due to effects of chloroquine on CYP2D6 inhibition, beta-blockers metabolized via CYP2D6 (such as metoprolol, carvedilol, propranolol, or labetalol) can have increased concentration of drug requiring careful monitoring for heart rate and blood pressure shifts. Lastly, both agents are associated with a conditional risk of torsade des pointes in patients with electrolyte abnormalities or with concomitant use of QT-interval--prolonging agents. Short-term exposure to these agents, as would be expected in treatment of COVID-19, confers lower risk of these dose-duration--dependent side effects.

Methylprednisolone is another drug under investigation that is currently being used to treat severe cases of COVID-19 that are complicated by ARDS ([@bib49]). A retrospective analysis in patients with COVID-19 who develop ARDS demonstrated that methylprednisolone use was associated with decreased mortality ([@bib28]). This steroid is known to cause fluid retention, electrolyte derangement, and hypertension as direct CV effects, and it also may interact with warfarin via an undescribed mechanism. Clinicians are advised to observe for these drug interactions.

Ibuprofen, a nonsteroidal anti-inflammatory agent, is often used as part of treatment of patients with viral illnesses. However, recent anecdotal evidence has raised wider concerns that the use of ibuprofen can potentially contribute to severe disease in patients with COVID-19 ([@bib84]). While data is limited, one of the working theories is that ibuprofen may interfere with the host's immune response to infection. Therefore, at least preliminarily, this mechanism for worse outcomes in patients taking ibuprofen does not appear to involve the CV system.

Finally, patient debilitation from severe COVID-19 may pose challenges in administering routine CV medications, ranging from antiplatelet therapy to beta-blockers, thus putting patients with or at risk of ischemic heart disease or heart failure at risk of further deterioration of their clinical condition.

ACE2 and potential therapeutic implications {#sec5.3}
-------------------------------------------

As the ACE2 receptor is the mechanism of entry for SARS-CoV-2, some data suggest that ACE inhibitors and angiotensin receptor blockers (ARBs) may up-regulate ACE2, thereby increasing susceptibility to the virus ([Figure 1](#fig1){ref-type="fig"}) ([@bib5]). In contrast, other studies show that ACE inhibitors/ARBs may potentiate the lung protective function of ACE2, by reducing angiotensin II levels through its conversion to angiotensin ([@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7],[@bib85], [@bib86], [@bib87]). Thus, the therapeutic implications for ACE inhibitor/ARB therapy during COVID-19 infection is unclear. Overall, there are insufficient data to suggest any mechanistic connections involving ACE inhibitor/ARB therapy with contracting COVID-19 or with severity illness once infected.

Considerations for Health Care Workers {#sec6}
======================================

Protective equipment for CV health care workers {#sec6.1}
-----------------------------------------------

The [Central Illustration](#undfig2){ref-type="fig"} demonstrates key considerations for treating patients in the current era of the COVID-19 pandemic. Early reports from the outbreak have suggested that transmission occurs most commonly via respiratory droplets that are produced when an infected individual coughs or sneezes. These droplets can land on exposed mucous membranes or be inhaled into the lungs of those within close proximity and the virus may remain active on surfaces for several days ([@bib88]). Whereas the Centers for Disease Control and Prevention had previously recommended airborne precautions for the care of patients with COVID-19, this recommendation was recently changed such that only patients undergoing aerosol-generating procedures require airborne isolation. Recommendations made by the World Health Organization and Centers for Disease Control and Prevention for personal protective equipment (PPE) are in agreement that standard, contact precautions with face mask, eye protection, gown, and gloves are necessary ([@bib53]). When available, respirators are preferred.Central IllustrationConsiderations for Patients, Health Care Workers, and Health Systems During the COVID-19 PandemicKey considerations for patients with established cardiovascular disease (CVD), patients without CVD, and for health care workers and health care systems in the setting of the coronavirus disease 2019 (COVID-19) outbreak. CV = cardiovascular; PPE = personal protective equipment.

In addition, when performing certain procedures that are aerosol-generating, such as transesophageal echocardiography, endotracheal intubation, cardiopulmonary resuscitation, and bag mask ventilation, additional PPE may be required, including controlled or powered air purifying respirators. Thorough infection prevention and control measures specific to the procedural cardiology specialties must be considered in light of the COVID-19 outbreak. Such procedures are associated with the small but quantifiable risk of complications and patient deterioration. In the event of a cardiac arrest, efforts at cardiopulmonary resuscitation causing aerosolized pathogens could result in the wide dissemination of virus particles to clinicians, health care workers, and other patients. One measure that may help protect health care workers in the setting of cardiac arrest and chest compressions is the use of external mechanical compression devices to minimize direct contact with infected patients. Another important consideration for the catheterization laboratory is appropriate post-intervention cleaning of all equipment potentially contaminated with SARS-CoV-2. The necessary downtime required for cleaning may seriously affect the availability of catheterization laboratory-based treatments for other patients. As such, many hospitals are minimizing or cancelling elective procedures during the growth phase of the outbreak. Another consideration is the fact that catheterization laboratories and operating rooms are typically configured with positive pressure ventilation, and there have been reports of centers in China converting such facilities to negative pressure isolation in the setting of COVID-19 ([@bib89]). Guidance and recommendations in this space will be forthcoming from interventional communities, including the American College of Cardiology and Society of Cardiovascular Angiography and Intervention ([@bib53]).

[Figure 3](#fig3){ref-type="fig"} depicts key information summarizing considerations to prevent infection among CV health care workers as summarized in an infographic. Overall, as CV health care workers are on the front lines treating COVID-19-infected patients, all possible measures should be implemented to reduce the risk of exposure ([@bib90]). Health care workers are at elevated risk for contracting this virus, as demonstrated by Wu et al. ([@bib16]), noting 1,716 of the 44,672 infected individuals (3.8%) were health care workers. This fact emphasizes the need for self-protection with PPE before caring for potentially exposed COVID-19 patients and provides further rationale for delaying elective procedures. In teaching hospitals, it is imperative to minimize exposure among trainees and nonessential staff (e.g., medical students) not only for their own safety and that of their patients, but also for conservation of PPE and for avoiding the unnecessary increase in the number of asymptomatic vectors. Finally, transmission between health care workers is also a major concern, especially in the setting of emergency or suboptimal logistics, or when devices for PPE have become scarce.Figure 3Considerations Regarding COVID-19 for Cardiovascular Health Care Workers by SpecialtyInfographic with important considerations regarding coronavirus disease 2019 (COVID-19) for cardiovascular disease health care workers by specialty. ACLS = advanced cardiac life support; CPR = cardiopulmonary resuscitation; PCI = percutaneous coronary intervention; PPE = personal protective equipment; TEE = transesophageal echocardiography.

Triaging CV patients and visits {#sec6.2}
-------------------------------

There are numerous considerations specific to the care of CV patients that should be taken into account to minimize risk for COVID-19 transmission to patients and health care workers; these considerations are outlined in [Table 6](#tbl7){ref-type="table"} . One important mechanism to help prevent transmission is the use of telemedicine. This technology, already used by numerous large health care systems around the world, is ideal in public health crises as it allows for patients to be triaged while minimizing exposure of patients and health care workers to potential infection. Additionally, telemedicine provides an opportunity for specialists that might not otherwise be available to evaluate patients. Although there are currently barriers to the widespread implementation of telemedicine, such as coordination of testing in patients triaged as high risk, this is a technology that will likely prove important to promote viral containment ([@bib91]). Other essential principles are to minimize nonessential/nonurgent in-person health care worker-patient interactions as much as possible (i.e., social distancing) and limit elective cardiac catheterization, operating room, and echocardiographic procedures. If such procedures are necessary, the number of required personnel should be kept to a minimum.Table 6Considerations for Cardiovascular Health Care Workers and Health Systems Regarding COVID-19 and CVDHealth Care WorkerHealth SystemsE-visits/telehealth for triage and patient management, when feasibleProviding and expanding the knowledge and infrastructure for e-visits/telehealthAdherence to guidelines for optimal use of PPEPreparing sufficient PPE for patient families and healthcare personnelSelf-reporting symptoms, if present, and halting the role as health care worker in case symptoms ariseImproving patient and public education regarding indications for quarantine versus hospital presentationLimit elective procedures (i.e. echocardiography, cardiac catheterization) if not urgent/emergentImprove testing availability so appropriate containment can be achieved[^17]

Considerations for Health Systems and Management of Noninfected CV Patients {#sec7}
===========================================================================

CV societal leadership {#sec7.1}
----------------------

Recently, due to potential health concerns for the CV health care workers and investigators, and to avert deterioration of the COVID-19 outbreak, the American College of Cardiology made the unprecedented but appropriate decision to cancel the 2020 Scientific Sessions meeting. Similarly, a number of medical conferences around the world are either being canceled or postponed ([@bib92]). Additionally, given the clear implications of this pandemic on CV care, numerous societies have already weighed in with guidance statements, which are summarized in [Table 7](#tbl7){ref-type="table"} . The American College of Cardiology Clinical Bulletin provides a practical clinical summary about key implications and recommendations for CV care of COVID-19 patients ([@bib93]). The European Society of Cardiology Council on Hypertension and European Society of Hypertension statements acknowledge the questions regarding ACE inhibitor and ARB therapy in the setting of COVID-19 patients ([@bib94],[@bib95]). These societies as well as a number of others agree that further data would be vital to inform decisions on adjusting regimens of these agents in the setting of this outbreak ([@bib96], [@bib97], [@bib98]). Moving forward, these important CV societies among other large physician groups and health systems will be critical allies to advance the knowledge generation and CV care in patients infected with this virus.Table 7CV Society Guideline Key Considerations With Regard to CVD and COVID-19Society/Guideline (Ref. \#)Key RecommendationsACC Clinical Guidance ([@bib93])Establish protocols for diagnosis, triage, isolation of COVID-19 patients with CVD or CV complications\
Develop acute myocardial infarction--specific protocols (i.e., PCI and CABG) for COVID-19 outbreakESC Council on Hypertension Statement on COVID-19 ([@bib94])There is insufficient evidence regarding the concerns surrounding safety of ACE inhibitor or ARB treatment in patients with COVID-19\
Current recommendations are to continue ACE inhibitor or ARB therapy given no sufficient evidence to discontinue therapy because of this infectionEuropean Society of Hypertension ([@bib95])Patients with hypertension should receive treatment with ACE inhibitors and ARBs according to 2018 ESC/ESH guidelines despite COVID-19 infection status ([@bib102])\
In, the case of shock, health care workers should continue or discontinue ACE inhibitor and ARB therapy on case-by-case basisHypertension Canada ([@bib96])Patients with hypertension should continue their home blood pressure medical regimenCanadian Cardiovascular Society ([@bib97])Continuation of ACE inhibitor, ARB, and ARNI therapy is strongly recommended in COVID-19 patientsInternal Society of Hypertension ([@bib98])Endorse the ESC Hypertension Statement[^18]

Preparing for hospital surges and prioritizing care for the critically ill {#sec7.2}
--------------------------------------------------------------------------

A comprehensive package of measures is required for hospital systems to fully prepare for COVID-19 ([Table 5](#tbl5){ref-type="table"}). A significant increase in COVID-19 patients should be anticipated. At the same time, provisions for general health services for acute and severe chronic illnesses must be maintained. Specifically, regarding CV care, as the pandemic surges, hospitals may prioritize the treatment of severe and high-risk patients and enact policy to prevent overwhelming of the health care system by the "worried well." Given concerns of hospitals exceeding capacity, specific protocols will need to be developed for the care of CV patients while preserving limited in-patient resources and minimizing health care worker and patient exposures. There are reports of individual centers developing alternate ST-segment elevation MI pathways in the setting of the COVID-19 crisis, such as using fibrinolytic therapy if delays to primary percutaneous coronary intervention are anticipated when hospitals are at capacity or staffing for the catheterization lab is inadequate ([@bib51]). A recent report from China also suggests substantial delays in door-to-device time in patients presenting with STEMI during the COVID-19 outbreak ([@bib99]). Additionally, repurposing cardiac ICUs as medical ICUs for the care of patients with COVID-19 will likely become necessary, but this may limit the quality of specialty care for CV patients. Given the need for ICU beds after cardiac surgery, medical management or percutaneous interventional approaches may need to be preferentially considered for urgent scenarios that cannot wait (e.g., percutaneous coronary intervention rather than coronary artery bypass graft surgery or transcatheter valve solutions rather than surgery) to minimize ICU bed utilization. Furthermore, as mentioned, appropriate use and careful selection of ECMO-appropriate patients as well as having established ECMO protocols for COVID-19 patients are important strategies to consider ([@bib60]).

Need for education {#sec7.3}
------------------

Information on the most up-to-date evidence surrounding management and treatment of patients with COVID-19 should be widely disseminated and freely available and should be provided in illustrative formats (e.g., infographics) that improve public knowledge and understanding. The free flow of communication between health care workers and hospitals is paramount to effectively combat the pandemic. The care of patients with COVID-19 will require the expertise of many specialty services including pulmonology/critical care, infectious diseases, cardiology, surgery, pharmacy, and hospital administration among others. Optimal infection control and treatment strategies for COVID-19 should be shared with the entire health care community. Accordingly, every effort must be made to provide clear and unambiguous information to patients and decision makers, countering myths and false news that may generate panic or false optimism. As the evidence base surrounding COVID-19 and its management is evolving on a daily basis, the dissemination of accurate information must occur in real time.

Ethical challenges {#sec7.4}
------------------

The unprecedented challenge represented by COVID-19 has brought novel and dramatic ethical dilemmas, ranging from policy issues (e.g., focusing on containment and mitigation vs. herd immunity), as well as clinical dilemmas (e.g., considering all patients alike vs. triaging patients according to age, comorbidities, and expected prognosis, similar to other catastrophic circumstances). Close interaction among patient advocates, government officials, and regulators, as well as physician groups, hospital administrators, and other societal leaders will be essential to navigate these ethical challenges.

Conclusions and Future Directions {#sec8}
=================================

The COVID-19 pandemic has affected hundreds of thousands of patients and poses a major health threat on an international scale. The CV community will play a key role in the management and treatment of patients affected by this disease in addition to providing continuity of care to noninfected patients with underlying CVD. In the coming months, efforts toward evaluating new therapies will be crucial to the treatment of this virus, and as this process develops, further appreciation of the intricate interplay among COVID-19, CVD, and the various stakeholders involved including patients, health care workers, and health care systems will be crucial to improving outcomes in at-risk and infected patients. Prospective randomized clinical trials and cohort studies are ongoing and will be important to helping treat patients affected by this virus.

A number of theories exist regarding the elevated risk for adverse events for patients with CVD who develop COVID-19. In particular, better understanding of the relationships involving the ACE2 protein, antihypertensive agent use, and COVID-19 prognosis will have important implications for patients with both COVID-19 and CVD. Outside of the scope of individual trials, concerted efforts by all health care workers and incisive leadership are required to help mitigate the health risk to the population at large, as well as to CV health care workers, as demonstrated by the difficult decision to cancel the 2020 American College of Cardiology Scientific Sessions. Efficient use of resources, including leveraging of the telehealth capabilities, and optimal adherence to preventative population-wide and health care worker-level measures will enable the transition from this critical period until the disease outbreak is contained.
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[^1]: Drs. Driggin and Madhavan contributed equally to this work.

[^2]: Values are n (%). To date, no publications have described these statistics for COVID-19 patients from other areas including South Korea, Iran, Italy, Spain, and others. Therefore, the comparator parent population was chosen from China.

[^3]: COVID-19 = coronavirus disease 2019; CV = cardiovascular; CVD = cardiovascular disease.

[^4]: These studies by Wu et al. ([@bib16]) and Fang et al. ([@bib98]) include a large, population-based dataset and a systematic review, respectively, from China that are inclusive of the other displayed cohort studies.

[^5]: Composite of CVD and cerebrovascular disease.

[^6]: Chinese population prior to COVID-19 included for comparison. Please note that disease ascertainment was different in this study compared with studies of patients with COVID-19.

[^7]: Values are n (%). Only a few studies with single-center experience have presented data to date, which limits the generalizability of the findings, and the confidence in the point estimates.

[^8]: ICU = intensive care unit; other abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^9]: This study used multivariable modeling for outcome of death for each CV risk factor for CVD.

[^10]: [Table 5](#tbl5){ref-type="table"} summarizes specific recommendations in the setting of medication interactions.

[^11]: AV = atrioventricular; DNA = deoxyribonucleic acid; RNA =ribonucleic acid; other abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^12]: Indicates drug class interactions.

[^13]: [Table 5](#tbl5){ref-type="table"} summarizes specific recommendations in the setting of medication interactions.

[^14]: ADHF = acute decompensated heart failure; CVA = cerebrovascular accident; IL = interleukin; NLRP3 = nucleoside-binding domain-like receptor protein 3; non-DHP CCB = non-dihydropyridine calcium-channel blocker; TIA = transient ischemic attack; VEGF = vascular endothelial growth factor.

[^15]: Indicates drug class interactions.

[^16]: AV = atrioventricular; BCRP = breast cancer resistance protein; ECG = electrocardiogram; INR = international normalized ratio; MOA = mechanism of action; non-DHP CCB = non-dihydropyridine calcium-channel blocker; OATP1B1 = organic anion transporting polypeptide 1B1.

[^17]: PPE = personal protective equipment; other abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^18]: ACC = American College of Cardiology; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; CABG = coronary artery bypass graft; ESC = European Society of Cardiology; PCI = percutaneous coronary intervention; other abbreviations as in [Table 1](#tbl1){ref-type="table"}.
